Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (449)	2/23/2005 9:11:53 PM
From: quidditch	Read Replies (1) of 946

Peter, on that score--top line data--could you review briefly the primary endpoint in terms of survival benefit? I believe benefit was to be measured vs. taxol, as the control arm. What was SPA's primary endpoint--was it in terms of weeks or months of benefit? And given Bianco's event analysis, the talk on the thread was that the trial had continued--i.e., "events" had been delayed--longer than was anticipated (by whom?), leading to speculation that the endpoint might well have been met. How much credence is to be given to that "event" analysis and the prolongation of the trial, if in fact that is what occurred? tia, quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next